Table 2.

Clinical characteristics according to study group

CharacteristicIndividuals with Normoalbuminuria, Reference Group(n = 74)Individuals with Microalbuminuria
Nondecliners(n = 43)Decliners(n = 28)
At enrollment into the Joslin Study or onset of microalbuminuria
    age (yr; median [25th, 75th percentiles])30 (25, 34)32 (25, 37)34 (30, 42)
    duration of diabetes (yr; median [25th, 75th percentiles])15 (8, 22)18 (11, 26)17 (12, 25)
    ever smokers (%)315163
    HbA1c (%; median [25th, 75th percentiles])8.2 (7.4, 8.8)8.9 (7.9, 9.8)9.0 (8.6, 10.7)
    cC-GFR (ml/min; median [25th, 75th percentiles])156 (142, 166)145 (133, 158)161 (138, 172)
At examination to evaluate serum and urinary markers of inflammation
    duration of microalbuminuria (median [25th, 75th percentiles]07.0 (6.0, 8.0)6.5 (5.5, 8.0)
    HbA1c (%; median [25th, 75th percentiles])7.5 (6.9, 8.2)8.0 (7.2, 8.7)9.1 (7.5, 9.9)
    systolic BP (mmHg; median [25th, 75th percentiles])115 (110, 124)120 (112, 135)127 (114, 137)
    diastolic BP (mmHg; median [25th, 75th percentiles])70 (68, 76)77 (69, 81)73 (69, 78)
    AER (μ g/min; median [25th, 75th percentiles])17 (12, 24)57 (37, 85)67 (47, 129)
    use of ACEI (%)46075
    use of statins (%)232136
    cC-GFR (ml/min; median [25th, 75th percentiles])142 (130, 151)126 (112, 136)106 (84, 122)
Annual rate of decline of cC-GFR during 8 to 12 yr of follow-up
    cC-GFR slope (%/yr; median [25th, 75th percentiles]−1.03 (−1.2, −0.7)−1.6 (−2.6, −0.4)−5.6 (−7.5, −4.2)